Rare Disease Drugs Deserve Lower Cost Sharing In Part D, McClellan Says
This article was originally published in The Pink Sheet Daily
Executive Summary
In a speech to an Oct. 24 conference on rare diseases and orphan drugs, former CMS Administrator Mark McClellan said drugs for rare disease should not be on the high-cost-sharing specialty tier of Medicare Part D formularies, which typically require coinsurance of 25% to 33%.